Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

This study is looking for adults aged 18 or over who have been diagnosed with generalised myasthenia gravis (gMG). Your gMG should have been confirmed by a doctor, based on specific criteria that indicate muscle weakness in more than one area of your body.

Importantly, your gMG must be linked to certain antibodies in your blood called 'AChR antibodies'. A blood test will confirm if you have these antibodies, as this study specifically targets this type of gMG.

There are also some reasons why you might not be able to join. For example, if you've had surgery on your thymus gland in the last year, or if you have certain problems with your thymus gland. You also can't take part if you've had a type of infection called Neisseria meningitidis, or if you are pregnant, breastfeeding, or planning to become pregnant during the study.

If you decide to take part, you'll be involved in the study for a certain period, which will be fully explained to you before you commit. You'll have regular visits to the clinic where the study team will monitor your health, perform examinations, and ask you about your symptoms. You'll receive either the study medication (ALXN1720) or a placebo, which you'll take as instructed. There will be blood tests and other assessments to track how you're responding to the treatment and to check for any side effects. After the main treatment period, there will be follow-up visits to ensure your well-being. All procedures, including the number of visits and their duration, will be thoroughly explained in the informed consent process.